The announcement comes on the heels of a new round of financing that will help double Concure's field sales organization and train new clinicians across the United States in making Breast Microseed Treatment® available for women seeking breast cancer treatment. Those who have contributed to this round of funding include notable Seattle-area business and community leaders such as Jeff Wright, Chris Ackerley and Craig Tall.
Breast Microseed Treatment® is a safe, effective and convenient solution that goes beyond traditional radiation for early-stage breast cancer patients. This technique, also known as low-dose-rate brachytherapy, is based on a similar method that has already been proven to successfully treat prostate cancer. What distinguishes this treatment from conventional radiation therapy is that it allows post-lumpectomy patients the chance to have a one-time, one-hour procedure, as opposed to more burdensome conventional radiation treatments that may last from three to six weeks and require daily visits to a radiation facility.
Ad Statistics
Times Displayed: 1581
Times Visited: 8 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
About Concure Oncology
Concure Oncology was founded with the mission of easing the burden for women facing early-stage breast cancer by providing a treatment option that is safe, effective, and convenient. Led by a nationally recognized team of leaders from the medical industry, the Seattle area company is working with medical centers across the U.S. to bring Breast Microseed Treatment® to patients everywhere.
SOURCE Concure Oncology
Back to HCB News
